Navigation Links
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING
Date:6/3/2008

with stage IIb, III or IV non-small

cell lung cancer (NSCLC) unsuitable for radical therapy" (Abstract number

3037):

About YM BioSciences

YM BioSciences Inc. is an oncology company that identifies, develops and commercializes differentiated products for patients worldwide. The Company has two late-stage products: nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor (EGFR) and is approved in several countries for treatment of various types of head and neck cancer; and AeroLEF(TM), a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl in development for the treatment of moderate to severe pain, including cancer pain.

This press release may contain forward-looking statements, which reflect the Company's current expectation regarding future events. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such factors include, but are not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time to time in the Company's ongoing quarterly and annual reporting. Certain of the assumptions made in preparing forward-looking statements include but are not limited to the following: that nimotuzumab will continue to demonstrate a competitive safety profile in ongoing and future clinical trials; that AeroLEF- will continue to generate positive efficacy and safety data in future clinical trials; and that YM and its various partners will complete their respective clinical trials within the timelines communicated in this release. We undertake no
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. YM BIOSCIENCES REPORTS NIMOTUZUMAB NSCLC CLINICAL DATA AT ASCO ANNUAL MEETING
2. YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB COLORECTAL CANCER TRIAL FIRST COHORT IS CLOSED TO ACCRUAL
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
5. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
6. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
7. Angiotech announces completion of Bio-Seal(TM) clinical trial enrolment
8. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
9. Monogram Announces Presentation of Clinical Data for the HERmark(TM) Breast Cancer Assay at the 44th ASCO Annual Meeting
10. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
11. Quest PharmaTech Announces Positive Results from Phase I Clinical Trial of its Photodynamic Therapy for Actinic Keratosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 Terascala, the industry leader ... Alan Swahn, a former vice president of product management ... vice president of marketing. Terascala’s software when combined with ... create the highest performance and most reliable solutions for ... guide Terascala’s channel expansion and broaden its product portfolio. ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
(Date:7/10/2014)... 10, 2014 Research and Markets ( ... "International Photonic Integrated Circuit (Monolithic Integration, Hybrid ... report to their offering. ... of photonic integration traces its roots in the ... of photonic integration went unexplored and unfulfilled for ...
(Date:7/10/2014)... the journal PNAS (Proceedings of the National Academy ... and sleep deprivation have a significant effect on our ... the best time of day to test for diseases ... medicines effectively. , Researchers from the University of Surrey ... links between sleep deprivation, body clock disruption and metabolism, ...
Breaking Biology Technology:Terascala Expands Executive Team 2Terascala Expands Executive Team 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2Time of day crucial to accurately test for diseases, new research finds 2
... Genetics, Inc., (Pinksheets: VRAL) and its President, Haig Keledjian, ... with Timothy and Thomas LLC ("T&T") and its principals ... Settlement ends the almost 5-year-old lawsuit between the parties ... the Northern District of Illinois, originally initiated in March ...
... ANNAPOLIS, Md., Jan. 28, 2011 Anyone curious about ... plasma contributes to lifesaving medicines can now learn about ... Plasma Protein Therapeutics Association (PPTA). "Becoming a Plasma Donor," ... a committed plasma donor at one of the 400-plus ...
... This release is available in Spanish and ... observed for eons. From this fibrous diet consisting mainly of ... substances of no nutritional value to most animals, ruminants manage to ... keepers. And now, the cow, or rather the network ...
Cached Biology Technology:Viral Genetics Settles Litigation and Reacquires African Rights for HIV/AIDS Products 2Viral Genetics Settles Litigation and Reacquires African Rights for HIV/AIDS Products 3New Video on Plasma Donation Available 2How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 2How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 3How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 4How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 5
(Date:7/10/2014)... or even improve the state of fisheries resources ... the Mediterranean has deteriorated over the past 20 ... species reported in the Cell Press journal ... for stringent monitoring of Mediterranean fishing activities, better ... in Mediterranean waters. , Their data show that ...
(Date:7/10/2014)... for Interdisciplinary Research (MIIR) and the Marshall University ... they will be partnering with an international biosciences ... the agreement with Shanghai-based HD Biosciences Co. Ltd., ... risks of discovery and development of these new ... property and commercialization rights to products developed through ...
(Date:7/10/2014)... incubator, received a $1.4 million federal grant to develop ... bleeding during brain surgery. , Surgeons can spray the ... solutions in the gel will cohere and control bleeding ... gel can shorten an intracranial surgery by 30- 45 ... patient,s skull to be open and less anesthesia, reducing ...
Breaking Biology News(10 mins):Mediterranean fish stocks show steady decline 2Marshall University to partner with international company in drug development venture 2A start-up at NJIT develops bleeding-control gel for brain surgery 2
... common drugs for advanced ovarian cancer: paclitaxel, cyclophosphamide, and topotecan. ... a patient is likely to respond. And, unfortunately, picking the ... this month,s issue of the journal PLoS ONE , ... study used a sophisticated model of ovarian cancer genetics to ...
... Mass. A Navy-sponsored project to design a biologically inspired, swimming ... common bending rules for the tips of wings, fins, flukes, ... animal species. The study, led by John H. ... in Woods Hole, where he is a visiting scientist, is ...
... , , , , ... , AUDIO: Falon Tilley and ... Click here for more information. , ... , , , , ...
Cached Biology News:COXEN model picks the best drug for ovarian cancer 2Quest for jellyfish robot leads to discovery of bending rules for animal wing, fin tips 2Healthy Lunchbox Challenge helps influence healthy eating habits in children 2Healthy Lunchbox Challenge helps influence healthy eating habits in children 3Healthy Lunchbox Challenge helps influence healthy eating habits in children 4
Shake 'n' Stack oven - New Model (includes 10 bottle capacity rotisserie, adjustable feet, drip tray, manual)...
... - Neurosphere is a system designed for ... neurospheres in a serum free environment. The kit ... which has been optimized for neural stem cell ... Genes & Development 10 :3129). Two growth ...
Request Info...
... RQ1 RNase-Free DNase is a ... single-stranded or double-stranded DNA to produce ... for use in applications where maintaining ... RQ1 DNase is qualified for use ...
Biology Products: